Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 1 Jun 2012

Li Longyun, Zhong Wei, Liao Meilin, Chen Li, Han Baohui, Guan Zhongzhen, Yu Shiying, Liu Xuyi, Wu Yilong, Jiang Guoliang, Xu Jianming, Chen Jia, Tao Min, Luo Rongcheng, Li Weimin, Xu Nong, Zhao Xiao, Wang Mengzhao

Abstract excerpt

BACKGROUND AND OBJECTIVE: The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary objective was to describe the quality of life (QoL), tumor control status, drug safety, and clinical/genomic features...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Gefitinib

Share to Quality of Life

Share to Quinazolines

Share to Safety

Share to Survivors

Source

Open in PubMed Open full text

Identifiers

PMID: 22681919
DOI: 10.3779/j.issn.1009-3419.2012.06.03
PMCID: PMC6000305

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].PMID 22681919Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.Semantic proximity Read ↗

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.Semantic proximity Read ↗

Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.Semantic proximity Read ↗

[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].Semantic proximity Read ↗

[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].Semantic proximity Read ↗

[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].Semantic proximity Read ↗

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.